Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)

Tipranks - Tipranks - Thu Jan 29, 6:40AM CST

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Supernus Pharmaceuticals, with a price target of $65.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Amsellem is a 4-star analyst with an average return of 6.6% and a 51.30% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Biogen.

In addition to Piper Sandler, Supernus Pharmaceuticals also received a Buy from Bank of America Securities’s Pavan Patel in a report issued on January 20. However, on January 15, TipRanks – OpenAI reiterated a Hold rating on Supernus Pharmaceuticals (NASDAQ: SUPN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $192.1 million and a GAAP net loss of $45.12 million. In comparison, last year the company earned a revenue of $175.69 million and had a net profit of $38.5 million

Read More on SUPN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).